Rein Therapeutics News and Activities

Rein Therapeutics is a company listed under the stock ticker ALRN (US).

Acquisition, funding and merger involving Rein Therapeutics.

• The new name of Aileron Therapeutics is Rein Therapeutics. (posted on January 13 2025).

View the org chart displaying its 11 main executives

Most searched biographies at Rein Therapeutics

• Brian Windsor, Director, President and Chief Executive Officer
• Josef Von Rickenbach, Chairman of the Board
• Reinhard Ambros, Director

Create your alert
to follow the executive moves at Rein Therapeutics.

Rein Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Rein Therapeutics

• Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer ― Aileron
• Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 ― Aileron
• Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer ― Aileron
• Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer ― Aileron Therapeutics
• Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference ― Aileron Therapeutics
• Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 ― Aileron Therapeutics
• Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual
• Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights ― Aileron Therapeutics
• Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights ― Aileron Therapeutics
• Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference ― Aileron Therapeutics
• View more press releases Close

Social media about Rein Therapeutics

• Rein Therapeutics on Wikipedia, Google News & Yahoo Finance
• Rein Therapeutics on LinkedIn, X (Twitter) & YouTube